Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ENROLLING BY INVITATION
NCT06880042
EARLY_PHASE1
COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO
Sponsor: Dr ayesha wahid
View on ClinicalTrials.gov
Summary
Patient of stable and limited vitiligo less than 20% BSA will be recruited And evaluation of efficacy and safety of narrowband UVB with topical tacrolimus vs narrowband UVB and calcipotriol will be assessed
Key Details
Gender
All
Age Range
15 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-05-01
Completion Date
2025-08-30
Last Updated
2025-06-24
Healthy Volunteers
Yes
Interventions
DRUG
Tacrolimus
Tacrolimus is calcineurin inhibitor that will act as immunomodulator
DRUG
Calcipotriol
Calcipotriol is a vitamin D analogue that will act as immunomodulator
Locations (1)
Lahore general.hospital
Lahore, Punjab Province, Pakistan